Blocking VEGFR-2 signalling is therefore seen as one of the most promising ways to prevent tumour-induced angiogenesis.27,28 Early antiangiogenic clinical trials focused on VEGF/VEGFR signalling blockade.29 The VEGF family is part of a broader category of signalling proteins known as cytokines. This evidence concerns the gene VEGFA and neoplasm.